Summary - October 2022

Following a poor September, capital markets experienced a strong October. The US Dow Jones Index posted its best October-month ever. Inflation numbers and thus interest rate hikes by central banks continued to take center stage. Fears that aggressive hikes would lead to a recession were mitigated by strong labor statistics, especially in the US.

Value stocks outperformed growth stocks

As far as Q3 earnings were concerned, outcomes were generally better than expected (or feared). However, reports from the largest tech companies were received poorly and October marked the largest stock outperformance for value ahead of growth for a single month in many years.

Further interest rate hikes

Many central banks, including the Federal Reserve and the ECB, lifted rates as inflation continued to be elevated. The so-called pivot (when rate hikes inflect) still seemed some way off, even though a less aggressive hike than expected by the Canadian central bank was seen by investors as a sign of a more dovish direction. However, most analysts believed a more benevolent stance by central banks would not be seen until fund rates were considerably higher than the current levels.

Eight long months of war

The Russian aggression towards Ukraine went into its eighth month. A Ukrainian counter-offensive was met by terror bombings by Russia, targeting civilians and infrastructure objects leading to significant casualties as well as widespread blackouts. At the very end of October, Russia unilaterally decided not to prolong the UN[1]designed export of grain from Ukrainian harbors. The US and the EU continued to show resolve in their support for Ukraine.

Re-election at the Chinese party congress

In China, the 20th communist party congress re-elected President Xi for a third term. Furthermore, the central committee was reshuffled in a way which further consolidated Xi´s power. Investors reacted negatively to what was seen as a further pull-back from market reforms and the Hang Seng index in Hong Kong fell to multiyear lows.

Continued turmoil in the UK

The turmoil in UK politics continued. Liz Truss will go down in history as the most short-lived PM in history (44 days) and was succeeded by former chancellor Rishi Sunak. Determined not to make the same mistake as his predecessor, Mr Sunak pushed his budget announcement into November. The volatile markets for UK currency and bonds thus calmed down.

Energy worries ahead of the winter season

Energy continued to be in focus ahead of the winter season. The Biden administration made additional drawdowns to the Strategic Petroleum Reserves, all in order to mitigate US consumer pain at the gas pumps ahead of the mid-term elections. In Europe, natural gas supplies were sufficiently restored, even though prices were several times higher than in the US. The decision of OPEC+ to cut production by two million barrels per day was condemned by the US. The world index thus increased in October. All sectors posted gains, albeit with great dispersion, with energy being by far the best performer, followed by industrials and financials. At the other end, consumer discretionary and utilities lagged the overall market. As far as regions were concerned, all major regions noted gains with one exception; Hong Kong, which saw its benchmark index fall double digit.

The strong performance in October was a welcome bounce from a tepid third quarter and a rather weak year overall.

“The Presidential cycle effect”?

History shows a surprisingly marked and consistent pattern of weak starts in the midterm election year during a president’s first election period. One explanation could be the rather tense relationship between a new president and a likewise new congress. Both determined to set the political agenda and whereby the congress can make it difficult for the president to be able to deliver on election promises. Promises which could have been good or detrimental to the profitability of public companies. Also, completely new budgets take time to be negotiated and implemented which probably lead to such periods being less fiscally expansionary. Importantly, history also tells us that the period after midterm elections during a president’s first election term is usually very strong for the stock market all the way through to the next the presidential election.

Reasons to think it could be different this time

It would seem then that a promising time is ahead of us. However, unfortunately it could be different on this occasion. The reasons for this are the current strong inflationary environment and the tense, very ideologically competitive atmosphere between the Western democracies on one side and China, Russia and Iran on the other. Our current judgement is that the historical pattern of a period of strength will dominate over current issues. We believe inflation should peak soon and the war in Ukraine does not seem to be spilling over into other countries, at least not yet. The risk for a classic recession is not to be underestimated and the evolution of FED’s interest rate policy to combat inflationary pressure is certainly not completely known, which makes predictions of relative subsector attractiveness and returns quite difficult.

More articles

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

EN